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Human Herpesvirus 8 as a Potential Sexually Transmitted Agent in Honduras
C. Sosa, W. Klaskala, B. Chandran, R. Soto,
L. Sieczkowski, M. H. Wu, M. Baum, and C. Wood

School of Biological Sciences, University of Nebraska-Lincoln, Lincoln,
Nebraska; Department of Psychiatry, University of Miami School of
Medicine, and Fogarty International Training Center, Department of
Psychiatry, University of Miami School of Medicine, Miami, Florida;
Department of Microbiology, Molecular Genetics and Immunology,
University of Kansas Medical Center, Kansas City, Kansas

The seroprevalence of human herpesvirus 8 (HHV-8) was studied in 326 human immunodeficiency
virus (HIV) – positive and – negative persons from Honduras; women constituted 77% (n Å 251) of
the subjects. Sera were tested for lytic HHV-8 antibodies by an IFA, and positive samples were
confirmed by a radioimmunoprecipitation assay. Of the 326 persons tested, 58 (17.8%) had HHV8 antibodies. Among the HIV-infected women, 22.7% were seropositive; 11.3% of the HIV-negative
women were seropositive. HHV-8 seroprevalence was almost four times higher in HIV-positive
female commercial sex workers (36%) than in HIV-negative female non – commercial sex workers
(9.9%; odds ratio Å 3.8, 95% confidence interval Å 1.1 – 13; P Å 0.01), suggesting that commercial
sex work is a risk factor for HHV-8 infection. In the men studied, the overall HHV-8 seroprevalence
was 22.6%, with a seropositivity rate of 28% for HIV-positive men compared with 12% for HIVnegative men.

Human herpesvirus 8 (HHV-8) has been detected in Kaposi’s
sarcoma (KS) tumors of all clinical forms [1], in lymphomas
[2], in Castleman’s disease [3], and in skin cancers [4]. Several
B lymphoma cell lines that harbor HHV-8 have been established and used for serologic assays [5, 6]. IFA showed that
most KS patients have specific antibodies to HHV-8 – related
antigens [7]. In another study, which used a Western blot assay,
an HHV-8 seroprevalence of 80% was reported for KS patients
but for only 18% of human immunodeficiency virus (HIV) –
positive homosexual men without KS. No positive samples
were identified among healthy blood donors or HIV-positive
men with hemophilia [8]. Similar results were found using a
recombinant-based Western blot assay: 84% in KS patients,
1.19% in HIV-positive hemophilic patients, and 3.17% in HIVpositive intravenous drug users [9].
HIV-positive homosexual men develop KS at a rate 20,000fold higher than that in the general population [10]. In contrast,
the incidence of KS in HIV-positive women is only 1% – 3%
[10, 11]. Recently, a study by Kedes et al. [12] found HHV-8
antibodies in only 4% of HIV-positive versus 1.2% in HIVnegative American women [12]. In contrast, another study
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showed HHV-8 antibodies in 21% of a small group of HIVpositive women, in ú95% of HIV-infected homosexual men
without KS, and in 25% of healthy adults [13].
The aim of our work was to determine the HHV-8 seroprevalence and associated risk factors in a population of women and
men in Honduras; in Latin America, the incidence of KS is
low. Determination of the HHV-8 infection in men and women
of this area should provide important information about the
distribution of and risk factors for HHV-8 infection.

Materials and Methods
Patients. Men and women (n Å 326) attending public clinics
in five cities in Honduras (Tegucigalpa, San Pedro Sula, Comayagua, La Ceiba, and Puerto Tela) were enrolled in the study, which
is part of an ongoing study on HIV infection by the University of
Miami. The clinics belong to the Honduran Ministry of Health
and provide services free of charge to the general population.
Participants represented a cross-sectional sampling of the population and were recruited from the five previously mentioned major
public care centers. We deliberately recruited known HIV-positive
individuals when they came for health care so they would comprise
Ç50% of the study population. Individuals were enrolled consecutively into the study during their routine medical checkups at the
clinics. All eligible participants were included in the study; however, subjects who attended the clinics more than once were not
reenrolled in the study.
Participants with AIDS, intravenous drug users, and hemophiliacs were excluded by chart review because the aim of the study
was to assess factors contributing to sexual transmission of HHV8. Intravenous drug usage and blood transfusion would add a noncontrolled additional risk to the study, such as acquiring HHV-8
by needle sharing or by contaminated blood. Patients with AIDS
were excluded because the purpose was to evaluate persons with
intact immune systems in an asymptomatic population.
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A questionnaire was administered to collect sociodemographic
characteristics and HIV and HHV-8 risk factor information. It
provided information on the age of first sexual intercourse, type,
condom use, and history of sexually transmitted diseases. The
lifetime number of sex partners was not available; however, the
number of partners in the prior 12 months was self-reported by
study participants.
Blood samples were collected for HHV-8 serology and other
tests. Blood samples from all self-reported HIV-positive individuals were tested by ELISA and Western blot at the University of
Miami School of Medicine. Patients who tested positive for HIV
received counseling at the clinics. HHV-8 testing was not available
at the clinics at that time, so information about HHV-8 serologic
status was not given to the patients.
HHV-8 IFA. IFA was performed to detect HHV-8 antibodies
according to described procedures [13]. An HHV-8–positive cell
line (BCBL-1; from M. McGrath and D. Ganem via the AIDS
Repository Program [6], NIH), an HHV-8–negative cell line
(BJAB), and an Epstein-Barr virus (EBV) producer cell line
(P3HR-1) were used. Cells were induced with tetradecanoyl phorbal acetate (TPA) and spotted onto slides. Samples were examined
using an epifluorescent microscope, and technicians were not
aware of the IFA or radioimmunoprecipitation (RIP) results. All
samples were coded, and an inverse antibody titer §10 was considered positive.
A reference patient serum (HIV-positive, KS-positive) showed
distinctive IFA lytic patterns of bright, punctuated nuclear and
cytoplasmic staining in induced BCBL-1 cells. Control normal
serum showed no staining. Lytic antigen expression was further
confirmed with an HHV-8–specific anti–ORF 59 monoclonal antibody (11D1). Due to the discrepancies in previous seroprevalence
studies, 1:10 and 1:40 cutoff dilutions were both used, and the
positive samples were titrated (1:10–1:1280). To eliminate the
possibility of EBV cross-reaction, the 1:10 dilution–positive samples were preadsorbed using lysates from an EBV producer cell
line (P3HR1). The diluted sera were incubated with cell lysates
from 1 1 107 TPA-stimulated P3HR1 cells, and absorbed versus
unabsorbed samples were compared. HHV-8–specific fluorescent
patterns were maintained after absorption, indicating that reactivities at the 1:10 dilution were not due to cross-reaction with EBV.
HHV-8 RIP and SDS-PAGE analysis. Ten million uninduced
or TPA-induced (4–5 days after induction) BCBL-1 cells were
labeled for 20 h with 25 mCi/mL [35S]methionine (Tran35S label,
specific activity, 1177 Ci/mmol; ICN, Irvine, CA). Immunoprecipitation was done as described elsewhere [14]. RIP was performed
with all 1:10 IFA–positive samples to confirm these results.
Statistical analysis. The univariate analysis was used (Epi
Info, version 6.0; CDC, Atlanta) to assess the relative importance
of various risk factors for HHV-8 infection. Medians and percentages were calculated to compare variables across sexual groups
and their serologic status. Associations with HHV-8, as well as
with HIV and dual HIV plus HHV-8 seropositivity, were measured
with odds ratios (ORs) and 95% confidence intervals (CIs).

Results
Demographics and risk factors. Of the 326 participants
recruited, 77% were women (median age, 27 years), and 91%
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Table 1. HHV-8 and human immunodeficiency virus (HIV) seroprevalences in selected groups.
HHV-8 – positive†
Cutoff point
HIV serologic
status*
Women (total Å 251)
Non – sex workers
Commercial sex workers
Men (total Å 75)
Homosexual
Heterosexual
Total study population Å 326

(/)
(0)
(/)
(0)
(/)
(0)
(/)
(0)
(/)
(0)
(/)
(0)
(/)
(0)

110
141
85
71
25
70
50
25
20
2
30
23
157
169

(43.8)
(56.2)
(33.9)
(28.3)
(10.0)
(27.9)
(66.7)
(33.3)
(26.7)
(2.7)
(40.0)
(30.7)
(48.2)
(51.8)

1:10
25
16
16
7
9
9
14
3
7
0
7
3
39
19

(22.7)
(11.3)
(18.8)
(9.9)
(36.0)
(12.9)
(28.0)
(12.0)
(35.0)
(23.3)
(13.0)
(24.8)
(11.2)

1:40
7
5
3
2
4
3
4
0
2
0
2
0
11
5

(6.4)
(3.5)
(3.5)
(2.8)
(16.0)
(4.3)
(8.0)
(10.0)
(6.7)
(7.0)
(3.0)

NOTE. Data are no. (%).
* Percentages were calculated based on total no. of women or men.
†
Percentages were calculated based on HIV serologic status of subgroup.

were single. They had õ6 years of formal education, and the
majority were of low socioeconomic status. Of all individuals,
56% lived on the Atlantic coast area, and 44% lived in the
country’s interior. First sexual contact was reported at a median
age of 15 years. More than 52.4% of the participants acknowledged the use of noninjected drugs, mainly cocaine and alcohol.
Almost all knew about condoms, but only 37% acknowledged
consistent usage. A history of sexually transmitted diseases
was reported by 34.4% of the participants.
HHV-8 seroprevalence. The frequency of HHV-8 – positive samples at the 1:10 and 1:40 dilutions was determined
(table 1). Of the 326 persons tested, 58 (17.8%) were positive:
41 (16.3%) were women, and 17 (22.6%) were men (table 2).
Among the HIV-infected women, an overall HHV-8 seropositivity of 22.7% (25/110) at the 1:10 dilution and 6.4% (7/
110) at the 1:40 dilution was found (table 1). In contrast, the
seropositivity of HHV-8 among HIV-negative women was
11.3% (16/141) at the 1:10 and 3.5% (5/141) at the 1:40 cutoff.
In the univariate analysis, there were differences between the
proportion of HIV-positive and HIV-negative women who
were infected with HHV-8. The HHV-8 seroprevalence was
almost four times higher among HIV-positive female sex workers (36%) than among HIV-negative non – commercial sex
workers (9.9%; OR Å 3.8, 95% CI Å 1.1 – 13; P Å .01), suggesting that prostitution and HIV are risks associated with
HHV-8 infection. Information about the numbers of lifetime
sex partners from these two groups of women were not available; however, the correlation between the number of sex partners in the prior 12 months and HHV-8 serologic status was
not significant. Our interpretation could still be affected due to
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Table 2. Study groups and selected HHV-8 risk factors.

Women
Men
Total
Risk factors
Homosexual male contact
Female sex worker
Drug use history
Never use condoms
History of STDs
Abnormal Pap smear

Total

HIV-positive

HHV-8 – positive*

HIV/HHV-8 – positive

251
75
326

110 (43.8)
50 (66.6)
160 (49.0)

41 (16.3)
17 (22.6)
58 (17.8)

25 (9.9)
14 (18.6)
39 (12.0)

7
18
37
25
25
14

7
9
23
17
18
13

22
85
171
143
112
76

20
25
89
80
76
43

(90.9)
(29.4)
(52.0)
(55.9)
(67.8)
(56.6)

(31.8)
(21.2)
(21.6)
(17.5)
(22.3)
(18.4)

(31.8)
(10.6)
(13.4)
(11.9)
(16.1)
(17.1)

NOTE. STDs, sexually transmitted diseases; HIV, human immunodeficiency virus.
* Based on 1:10 dilutions of serum samples.

the limited data on the types of sex partners and the duration
of commercial sex work of these women. In men, the overall
HHV-8 seroprevalence was 22.6% (17/75) (table 2). The rate
of HHV-8 infection in HIV-positive men was more than twice
as high as in HIV-uninfected men at the 1:10 dilution (28%
vs. 12%) (table 1), but these results were not statistically significant due to the small sample size.
There were also differences in the univariate analysis of the
risks associated with different behaviors (table 2): Being a
homosexual male (OR Å 10.0, 95% CI Å 1.3 – 92.9, P Å .009),
engaging in sexual intercourse at early age (comparison of
means, 14.6 years, 16.4 years; P Å .01), history of sexually
transmitted diseases (OR Å 3.5, 95% CI Å 1.6 – 8.0; P Å .01),
and abnormal Pap smear (OR Å 5.2, 95% CI Å 1.7 – 15.9; P
Å .006) were significantly associated with dual HIV/HHV-8
seropositivity. All variables associated with HIV/HHV-8 seropositivity or with an OR õ 0.75 or ú1.5 were then entered
into a logistic regression model. First sexual activity at §16
years old (adjusted OR Å 0.4; 95% CI Å 0.2 – 0.8; P Å .011)
and being male (adjusted OR Å 3.0, 95% CI Å 1.3 – 7.0; P Å
.012) were independently associated with dual HIV/HHV-8
infection. Among the small group of HIV-infected men studied,
sexual orientation was not statistically associated with HHV8 serologic status (OR Å 1.7, 95% CI Å 0.5 – 6.1; P Å .4).
RIP. To confirm that weak positive sera (1:10 titer) were
indeed positive, RIP was performed. Positive sera recognized
at least 20 polypeptides in induced BCBL-1 cells, which are
probably proteins associated with lytic HHV-8 antigens (figure
1, lanes 1, 5, 7, 9, 11 [uninduced] and lanes 2, 6, 8, 10, 12
[TPA-induced]). IFA-negative sera did not show a specific
reaction in RIP (figure 1, lanes 3, 4). All sera recognized 155-,
116-, 105-, 90-, 55-, 50-, 38-, 29-, and 23-kDa polypeptides
from induced cells. Studies indicate that the 116-, 110-, 90-,
70-, 55-, and 50-kDa proteins are HHV-8 glycoproteins [14].
Only a weak reaction was seen in the uninduced BCBL-1 cells,
and only a limited number of polypeptides (225-, 145-, 74-,
70-, 55-, and 23-kDa) were immunoprecipitated. Positive RIP
criteria were established on the basis of the appearance of
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reacting viral proteins of the expected sizes: 225, 145, 74, 70,
55, and 23 kDa.

Discussion
To our knowledge, this is the first comprehensive study to
determine the prevalence of HHV-8 infection in a Latin American country. Our data extend previous serologic reports [7]
linking high HHV-8 seroprevalence with HIV coinfection. Evidence of strong association between HHV-8 and HIV infections
is supported in this study by the fact that HIV-positive women
have almost twice the risk of HHV-8 infection than a similar
group of HIV-negative women. We chose this group because
the HIV-positive women were very likely to be infected heterosexually and were available for follow-up studies to correlate
the incidence of HHV-8 infection with KS development.
A noticeable lack of consistency in the reported literature
of HHV-8 seroprevalence could be related to poor sampling
methods, different levels of test sensitivity (1:10 dilutions vs.
1:40 as a final cutoff point), and possible variations in assay
formats, including the detection of lytic or latent antibodies.
Nevertheless, the unique epidemiology of KS seems to support
the hypothesis that the cause of KS is multifactorial and that
one of the cofactors (necessary or enhancing factors) is HHV8, which predisposes HIV-positive persons to KS.
We chose to consider all sera showing reactivities at a 1:10
dilution or above as seropositive in this study because this
dilution includes more infected patients and, consequently,
shows a more realistic distribution of HHV-8 – infected persons.
Because all these samples were first absorbed with EBV cell
lysate to remove cross-reactivity, we are confident that they
reacted solely with HHV-8 antigens. Furthermore, all samples
were tested blindly by IFA at different sites (Nebraska and
Kansas), and all weakly reactive samples were confirmed by
RIP. Finally, our study included a negative control group, providing additional confidence that any bias found in the HIVpositive group would also be found in the control group.
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Figure 1. Radioimmunoprecipitation of selected samples: Lanes 1, 3, 5, 7, 9, and 11 are uninduced BCBL-1 cells. Lanes 2, 4, 6, 8, 10, and
12 are tetradecanoyl phorbal acetate – induced BCBL-1 cells. All cells were labeled with [35S]methionine for 20 h. Lanes 1 and 2 are sera that
were human immunodeficiency virus – positive (HIV) and HHV-8 positive by IFA at titer of 1:640. Lanes 3 and 4 are HIV-positive and HHV8 – negative (IFA õ 1:10). Lanes 5 – 12 are sera positive for HHV-8 by IFA.

Lennette et al. [10] analyzed a small number of HIV-positive
women and reported an HHV-8 seroprevalence (21%) similar
to that in our study. However, in the HIV-negative group, they
detected a higher rate (28%). Our study with HIV-positive
women showed higher rates than those reported by Kedes et
al. [13]. This may be explained by the cutoff (1:40) used in
that study.
The analysis of the occupation of women in our study demonstrated no increase in the risk of HHV-8 infection among
HIV-negative prostitutes. In contrast, the HIV-positive prostitutes had a strikingly increased risk of HHV-8 infection. We
found a rate of 35% in our population of HIV-positive homosexual men. The higher rate of KS among HIV-infected homosexual men may be explained by a higher incidence of HHV8 infection among these persons as well as the association with
specific sexual practices that are typical for this population
[15]. Two other IFA studies [8, 9] gave results concordant with
those of our investigation. However, these rates contrast with
the 18% seropositivity found by the study of Gao et al. [7], in
which latent antigens were measured, and suggests that the
titer of lytic antibodies may differ from those of the latencyassociated antigens.
Our study has determined the HHV-8 seroprevalence in a
Latin American country and suggests that HIV-positive women
have almost twice the risk of acquiring HHV-8 than an HIV-
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negative group. These results could be biased because a significant proportion of the HIV-positive women were commercial sex workers; however, having multiple sex partners does
seem to be a major risk factor for HHV-8 infection, suggesting
that HHV-8 can be transmitted heterosexually.
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A Randomized, Controlled, Molecular Study of Condylomata Acuminata
Clearance during Treatment with Imiquimod
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Imiquimod, an immune response modifier, has been demonstrated to be safe and effective in the
treatment of external genital and perianal warts caused by human papillomavirus (HPV). To identify
the molecular mechanism(s) by which condylomata acuminata clear during topical treatment with
imiquimod, wart skin biopsies were taken from patients before treatment, at treatment week 6, and
at the end of treatment. Tissues were analyzed for HPV DNA and for mRNA of several cytokines
and HPV gene products. Wart clearance was associated with evidence of tissue production of
interferon-a, -b, and -g and tumor necrosis factor-a. Regression of warts was strongly associated
with a decrease in HPV DNA and in mRNA expression for both early and late viral proteins. Thus,
topical imiquimod treatment of anogenital warts led to significant increases in local production of
multiple interferon mRNAs and a significant reduction in virus load as measured by decreases in
HPV DNA and mRNA for early HPV proteins.

Human papillomavirus (HPV) is the most common sexually
transmitted viral disease. About 1% – 2% of the sexually active
population in the United States has genital or perianal warts
(condylomata acuminata), caused mainly by HPV types 6 and
11 [1]. Current therapies include ablation by cryotherapy, surgi-
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cal excision, electrocautery, or laser, as well as cytodestruction
with podophyllin, podophyllotoxin, or trichloroacetic acid, suggesting no clear preference for therapy. The traditional goals of
sexually transmitted disease therapy — eradication of infection,
elimination of symptoms, prevention of long-term sequelae,
and interruption of transmission — have not been attained for
genital warts [2]. The lack of a sustained adaptive immune
response seems to underlie disease, as evidenced by frequency
of HPV disease in immunosuppressed patients [3].
Spontaneous regression of anogenital warts occurs in 10% –
30% of patients receiving placebo and is associated with cellmediated immunity (CMI) [3, 4]. This suggests that immune
enhancement may be an alternative to the purely destructive
therapies described above. Until recently, injectable interferon
(IFN), primarily IFN-a, has been the only available therapy
able to induce immune-mediated clearance of anogenital
warts. Patients with warts that respond to IFN therapy have
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